Promoter holding
64.27%
LT
Lambda Therapeutic Research Limited - Due diligence report
A 360° intelligence report on Lambda Therapeutic: trust score, financial health, credit view, compliance, directors, growth and distress sig…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Lambda Therapeutic — 360° Intelligence Report
Generated from MCA filings & public records76/100
Trust Score
Low Risk
Lambda Therapeutic is assessed as Low Risk with a Trust Score of 76/100. Lambda Therapeutic is an active public limited indian non-government company incorporated in 1998, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 07 Jul 2026 from the latest processed filings. Lambda Therapeutic Research Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
76/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
70/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
80/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (AA-).
Charges position: 3 open (22.00 cr) · 8 satisfied (281.49 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| The Royal Bank Of Scotland N.V. | 1 | 48.0 cr |
| Axis Bank Limited | 1 | 48.0 cr |
| Abn Amro Bank N.V. | 2 | 48.0 cr |
| Standard Chartered Bank | 2 | 48.0 cr |
| Others | 2 | 48.0 cr |
| Idbi Bank Limited | 1 | 48.0 cr |
Compliance Score: 70/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 3 court forum(s).
- 1 auditor resignation(s) filed - latest: Apaji Amin & Co. LLP on 2018-09-04.
- 2 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 80/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| BINDI BINISH CHUDGAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SURENDER TUTEJA KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NIKUR DILIPKUMAR MODY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| BINISH HASMUKH CHUDGAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RIKIN DILIPBHAI MODY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| TILOKCHAND PUNAMCHAND OSTWAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Melarkode Subbaraman Ramakrishnan | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 7 directors on the board.
- No disqualified or deactivated DINs.
- 4 director exits in 3 years - high churn.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
0 allotment(s) · 1 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Jina Pharmaceuticals Inc Usa | Subsidiary Company | 74.00% |
| Lambda Clinical Services Limited | Subsidiary Company | 74.00% |
| Lambda Therapeutic Ltd. Uk | Subsidiary Company | 74.00% |
| Lambda Therapeutic Research Inc. Usa | Subsidiary Company | 74.00% |
| Novum Pharmaceutical Research Services, Inc., Canada | Subsidiary Company | 74.00% |
| Lambda Therapeutic Research Sp Z.o.o Poland | Subsidiary Company | 74.00% |
Key managerial personnel: BINDI BINISH CHUDGAR (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 70 · Distress 65
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Asset base grew 2.1x - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 27+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
3 director exits within 2 years.
3 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence70/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment80/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 22.00 cr already registered.
- Compliance record supports lending.
Investor view73/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events29 Nov 2025
Director appointed
Melarkode Subbaraman Ramakrishnan (Whole-Time Director)
30 Sep 2025
Last AGM held
Annual general meeting
29 Sep 2025
Director ceased
TILOKCHAND PUNAMCHAND OSTWAL
11 Jul 2025
Director appointed
TILOKCHAND PUNAMCHAND OSTWAL (Director)
31 Mar 2025
Director ceased
BINDI BINISH CHUDGAR
Latest balance sheet
Filed with ROC
30 Sep 2024
Director ceased
PIYUSH JASHAWANTLAL SHAH
14 Dec 2023
Director ceased
SURENDER TUTEJA KUMAR
04 Jul 2023
Director appointed
SURENDER TUTEJA KUMAR (Director)
26 May 2021
Charge satisfied
Axis Bank Limited
17 Sep 2018
Charge satisfied
Idbi Bank Limited
30 Sep 2015
Director ceased
NIKUR DILIPKUMAR MODY
31 Mar 2015
Share transfer (FY 2015)
100.00000000 shares to DILIP NIKUR
16 Oct 2014
Director appointed
NIKUR DILIPKUMAR MODY (Director)
23 Aug 2013
Charge satisfied
Abn Amro Bank N.V.
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Net worth is positive.
7 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of AA- from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
61 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Bostonscientific | U73100DL2015FTC279809 | New Delhi, Delhi, India |
| Fev | U34300DL2006PTC146790 | New Delhi, Delhi, India |
| Aurigene Pharmaceutical | U74999KA2019PLC127964 | Bangalore, Karnataka, India |
| Sabic Research & Technology Private Limited | U74110KA1998PTC080762 | Bengaluru, Karnataka, India |
| Cliantha Research | U73100GJ2004PLC044669 | Ahmedabad, Gujarat, India |
| Ppd | U73100MH2004PTC144454 | Mumbai, Maharashtra, India |
| Rubicon | L73100MH1999PLC119744 | Thane, Maharashtra, India |
| Icon | U74110TN2004PTC054137 | Chennai, Tamil Nadu, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Lambda Therapeutic before audits and certifications: compliance score 70/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Lambda Therapeutic: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 70/100, margin trends, ownership structure and peer set for Lambda Therapeutic - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 76/100, distress signals and MSME payment-delay disclosures - know whether Lambda Therapeutic pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Lambda Therapeutic - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Lambda Therapeutic an active company?
Lambda Therapeutic has MCA status “Active” with a compliance score of 70/100 (Moderate).
Is Lambda Therapeutic financially healthy?
Lambda Therapeutic has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.
Should I do business with Lambda Therapeutic?
Its overall Trust Score is 76/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Lambda Therapeutic?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 7 active director(s) are on record.
Does Lambda Therapeutic have loans or charges against its assets?
3 open charge(s) are registered against its assets, and 8 earlier charge(s) stand satisfied.
Is Lambda Therapeutic up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 70/100 (Moderate).
Is it risky to lend to Lambda Therapeutic?
Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
